Bibiliografía

Eichinger S. Cancer associated thrombosis: risk factors and outcomes. Thromb Res. 2016;140 Suppl 1:12-7. [PubMed]

Farge D, Bounameaux H, Brenner B, Cajfinger F, Debourdeau P, Khorana AA, et al. International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol. 2016;17(10): e452-e466. [PubMed]

Francis CW, Kessler CM, Goldhaber SZ, Kovacs MJ, Monreal M, Huisman MV, et al. Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study. J Thromb Haemost. 2015.13(6):1028-35. [PubMed]

Jara-Palomares L, Solier-López A, Elías-Hernández T, Asensio-Cruz M, Blasco-Esquivias I, Marin-Barrera L, et al. Tinzaparin in cancer associated thrombosis beyond 6months: TiCAT study. Thromb Res. 2017;157:90-6. [PubMed]

Kearon C, Akl EA, Ornelas J, Blaivas A, Jiménez D, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest. 2016; 149(2):315-52. [PubMed]

Khorana AA, Carrier M, Garcia DA, Lee AY. Guidance for the prevention and treatment of cancer-associated venous thromboembolism. J Thromb Thrombolysis. 2016;41(1):81-91. [PubMed]

Lee AY, Kamphuisen PW, Meyer G, Bauersachs R, Janas MS, Jarner MF, Khorana AA; CATCH Investigators. Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial. JAMA. 2015;314(7):677-86. [PubMed]

Lee AY, Levine MN. Venous thromboembolism and cancer: risks and outcomes. Circulation. 2003;107(23 Suppl 1):I17–21. [PubMed]

Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, et al.; Hokusai VTE Cancer Investigators. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. N Engl J Med. 2018 Feb 15;378(7):615-24. [PubMed]

Van der Hulle T, den Exter PL, Planquette B, Meyer G, Soler S, Monreal M, et al. Risk of recurrent venous thromboembolism and major hemorrhage in cancer- associated incidental pulmonary embolism among treated and untreated patients: a pooled analysis of 926 patients. J Thromb Haemost. 2016;14(1):105-13. [PubMed]

Young AM, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C, et al. Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). J Clin Oncol. 2018 Jul 10;36(20):2017-23. [PubMed]